Balchem (BCPC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Annual Meeting scheduled for June 18, 2026, to be held virtually, with shareholders able to vote online or by proxy.
Key proposals include election of two Class 3 directors, ratification of the independent auditor, and advisory approval of executive compensation.
Strong financial performance in 2025: net sales up 8.8% to $1.037 billion, adjusted EBITDA up 9.8%, and adjusted net earnings up 17.4%.
Continued focus on innovation, sustainability, and risk management, including adoption of an AI Use Policy and enhanced cybersecurity training.
Voting matters and shareholder proposals
Shareholders will vote on: (1) election of two Class 3 directors (David Fischer and Daniel Knutson) to serve until 2029, (2) ratification of RSM US LLP as independent auditor for 2026, (3) advisory approval of executive compensation, and (4) other business as may arise.
Board recommends voting FOR all proposals.
Majority voting standard applies for uncontested director elections; broker non-votes and abstentions do not affect outcomes.
Board of directors and corporate governance
Board consists of seven members, six of whom are independent; average tenure is 7 years, 10 months, and average age is 63.
Board committees (Audit, Compensation, Governance, Executive) are composed solely of independent directors.
Board diversity includes gender, race, international experience, and a mix of new and experienced directors.
Annual self-assessments and regular succession planning are conducted.
Lead Director role reinforces board independence, especially with combined CEO/Chairman structure.
Latest events from Balchem
- Record Q1 sales, earnings, and cash flow with growth across all segments and improved margins.BCPC
Q1 20261 May 2026 - Virtual meeting to vote on directors, auditor, and executive pay set for June 18, 2026.BCPC
Proxy filing27 Apr 2026 - Record sales, earnings, and cash flow growth, with increased dividends and strong global expansion.BCPC
Q4 202520 Feb 2026 - Record Q2 earnings and margin gains led by Human Nutrition & Health and Specialty Products.BCPC
Q2 20242 Feb 2026 - Q3 2024 net earnings rose 16.4% on 4.3% higher sales, led by Human Nutrition & Health.BCPC
Q3 202418 Jan 2026 - Record Q1 sales, double-digit profit growth, and margin expansion across all segments.BCPC
Q1 202524 Dec 2025 - Record sales, profit, and cash flow growth, with strong innovation and sustainability progress.BCPC
Q4 20249 Dec 2025 - Record financials, sustainability gains, and strong governance drive all Board-backed proposals.BCPC
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and executive pay up for vote at June 2025 meeting.BCPC
Proxy Filing1 Dec 2025